MannKind Corporation Sets Q3 Earnings Release Date

MannKind Corporation (NASDAQ:MNKD) said Monday that it would release its fiscal third-quarter results on Monday, Nov.3 after the market close. The announcement will be followed by a conference call with investors and analysts  at 5:00 p.m. Eastern to discuss quarter results and other developments. You can participate in the live conference call by dialing (800) 708-4540 or (847) 619-6397. The participant passcode is: 3643 5007. Alternatively, you can listen to the call live through the company’s website.

MannKind’s Q3 loss expected to narrow down

The Valencia-based company is expected to start selling its inhaled insulin treatment Afrezza in early 2015. Analysts on average expect the company to incur a loss of 4 cents a share, narrower than a loss of 17 cents in the same quarter last year. They forecast revenue of $66.60 million. The company hadn’t generated any revenue in the corresponding quarter last year.

Notes From Schwarzman, Sternlicht, Robert Smith, Mary Callahan Erdoes, Joseph Tsai And Much More From The 2020 Delivering Alpha Conference

Stephen SchwarzmanThe following are rough notes of Stephen Schwarzman, Steve Mnuchin, and Barry Sternlicht's interview from our coverage of the 2020 CNBC Institutional Investor Delivering Alpha Conference. We are posting much more over the next few hours stay tuned. Q2 2020 hedge fund letters, conferences and more One of the most influential investor conferences every year, Read More


Shares of the company have declined close to 40% since June 30, despite FDA approval of Afrezza and worldwide commercialization agreement with French drugmaker Sanofi SA (ADR) (NYSE:SNY) (EPA:SAN). Goldman Sachs analyst Jay Olson said in a research note last month that MannKind will remain unprofitable on an annual basis at least until 2017.

Sanofi a good partner for MannKind

Even when the company begins turning profit in 2018, the profits will be small. Goldman Sachs’ EPS estimate is 70% lower than the Wall Street consensus for FY2018. The research firm says Sanofi could prove to be a good partner. The French company will try its best to retain its diabetes market share after its blockbuster Lantus goes off-patent. So, Sanofi will put its weight and marketing might behind Afrezza to make it a success.

However, Goldman Sachs says terms of the deal give the French company an upper hand. It may affect the profitability timeline of MannKind. Goldman Sachs as a Neutral rating on the stock with $6 price objective. Meanwhile, short interest in MannKind has skyrocketed from 47.46 million in January 2014 to 78.57 million shares at the end of September 2014.

MannKind shares inched up 3.81% to $6.00 at 11:00 AM EDT on Tuesday.